Clinical trials: Intravenous Steroid-Refractory Ulcerative Colitis
Intravenous Steroid-Refractory Ulcerative Colitis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.
- Trial name
- NCT00502294
- Testing
- Visilizumab (HuM291; Nuvion®)
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
- Trial name
- NCT00355901
- Testing
- Visilizumab (Nuvion®; HuM291)
- Where
- 40 sites in United States, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- PDL BioPharma, Inc.
Ulcerative Colitis
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
- Trial name
- NCT00307827
- Testing
- Visilizumab
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Abbott
Ulcerative Colitis
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
- Trial name
- NCT00279422
- Testing
- visilizumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 127 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.
- Trial name
- NCT00279435
- Testing
- visilizumab
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 25 people
- Sponsor
- Facet Biotech